Recent findings from a study published by GlobeNewswire reveal promising advancements in treating children diagnosed with achondroplasia using TransCon CNP (Navepegritide). The research highlights significant improvements in the growth rate and bone morphometry among participants. Achondroplasia, a genetic disorder characterized by dwarfism, sees a burgeoning hope with this innovative treatment modality, which addresses common growth challenges. Experts in the study noted that children treated with this compound experienced improvements in overall bone structure, which could lead to enhanced mobility and quality of life. TransCon CNP works by targeting growth factors essential for bone development, offering a potential breakthrough for pediatric patients globally. These findings present a compelling case for further investigation and possibly pave the way for wider clinical application, promising a new horizon for those affected by achondroplasia.
GlobeNewswireNew data shows return policies are deterring shoppers at checkout
February 17, 2026
A recent report highlights a growing ‘Returns Revolt’ among online shoppers, where restrictive return policies are significantly impacting e-commerce sales. According to the study, released